These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 8635092

  • 1. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D, Graziano F, Isidori P, Santo A, Cetto G, Fedeli A, Rossi G, Cellerino R.
    Cancer; 1996 Jun 01; 77(11):2251-7. PubMed ID: 8635092
    [Abstract] [Full Text] [Related]

  • 2. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.
    Cancer; 1996 Oct 15; 78(8):1701-7. PubMed ID: 8859183
    [Abstract] [Full Text] [Related]

  • 3. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Oct 15; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 Oct 15; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J.
    Lung Cancer; 2005 Apr 15; 48(1):129-35. PubMed ID: 15777980
    [Abstract] [Full Text] [Related]

  • 6. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G, Macciò A, Mulas C, Massa E, Madeddu C, Mura L, Contu P, Versace R.
    Oncol Rep; 2002 Apr 15; 9(3):661-70. PubMed ID: 11956647
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH.
    Cancer; 1998 Jan 15; 82(2):292-300. PubMed ID: 9445185
    [Abstract] [Full Text] [Related]

  • 13. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL, Sheen TS, Ko JY, Hsu MM, Wang CC, Ting LL.
    Br J Cancer; 1999 Aug 15; 80(12):1962-7. PubMed ID: 10471046
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 15. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
    Ajlouni M, Chapman R, Kim JH.
    Cancer J Sci Am; 1996 Jan 15; 2(6):314-20. PubMed ID: 9166551
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P, Iannucci A, Becker M, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.
    Melanoma Res; 2000 Apr 15; 10(2):171-9. PubMed ID: 10803718
    [Abstract] [Full Text] [Related]

  • 17. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 18. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun 15; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 19. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C.
    Tummarello D, Graziano F, Isidori P, Cellerino R.
    Cancer Chemother Pharmacol; 1995 Jun 15; 35(3):249-53. PubMed ID: 7528646
    [Abstract] [Full Text] [Related]

  • 20. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct 15; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.